No Data
No Data
Express News | Relmada Therapeutics Shares Are Trading Lower. The Company Reported Q2 Financial Results
Express News | Relmada Therapeutics Inc : Jefferies Cuts Target Price to $3.50 From $5.50
Express News | Relmada Therapeutics Q2 2024 GAAP EPS $(0.59) Beats $(0.81) Estimate
Express News | Relmada Therapeutics Inc: Cash Position of $70.4 Mln Provides Runway Through Key Milestones, Into 2025
Relmada Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
No Data